« Previous | Next » | All Messages |  NYMX Message Board Home | recommend post |  Ignore Poster

NYMX News Nymox Protein Biomarker for Alzheimer's is Years Ahead of Competition

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) AlzheimAlert™ test is literally years ahead of the competition, according to Brian Doyle, Nymox's Senior Manager for Worldwide Sales and Marketing. The urine-based test, which measures levels of a protein-based biomarker for Alzheimer’s disease, is currently available to physicians in major markets, including Europe and the United States. A recent article in The Wall Street Journal (“Detecting Alzheimer's Early,” December 12, 2006) described competing tests in this area that employ measuring multiple protein biomarkers and quoted a conservative estimate that these possible competitors were 3 to 5 years away from the clinic.

“Experience has shown that tests which require accurately measuring multiple putative biomarkers often have limited practical use outside of the research setting; these tests typically are difficult to repeat and hard to validate and rarely, if ever, make it to market,” said Brian Doyle. “They require in effect bringing many sophisticated diagnostic tests to market simultaneously with the added problem of how to interpret the many, sometimes conflicting, readings in the clinical context. By contrast, AlzheimAlert™ involves a single measurement of one biomarker and has over a decade of research, product development, and clinical validation behind it. Over the years, the AlzheimAlert™ technology has proven to be a valuable tool for physicians in the often difficult and frustrating task of diagnosing Alzheimer’s disease.”

The successful results of a multi-center double blind independent clinical study of the Company's urinary AlzheimAlert™ test were recently published in the Journal of the American Medical Directors Association (www.jamda.com). The independent peer-review study, “A Multi-Center Blinded Prospective Study of Urine Neural Thread Protein Measurements in Patients With Suspected Alzheimer's Disease,” was conducted double-blind at 8 specialist centers across the U.S. and involved expert assessments and state of the art clinical correlations and continued evaluations. The study results found the level of accuracy of the AlzheimAlert™ urine test to be over 90%.

AlzheimAlert™ is Nymox's proprietary urine based diagnostic aid for Alzheimer's disease. It is the only proven accurate non-invasive AD test technology available. The test has the CE Mark, allowing it to be marketed in Europe, and is also available to physicians in the U.S. through the Company's CLIA-certified Clinical Reference Laboratory in New Jersey at a cost of $295. Nymox currently has numerous initiatives underway for the AlzheimAlert™ testing technology, including marketing and distribution overseas, and global product development.

There are an estimated 4.5 million people with Alzheimer's disease in the United States alone; by 2050 this number is projected to increase almost three times to 13.2 million. Worldwide estimates of the current number of people with Alzheimer's disease range from 15 to 20 million. The annual national direct and indirect costs of caring for Alzheimer patients in the U.S. alone are estimated at $100 billion. The human toll on patients, families and caregivers is incalculable.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain “forward-looking statements” as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.